BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 35978529)

  • 1. Volumetric changes of the parotid gland during IMRT based on mid-treatment imaging: implications for parotid stem cell sparing strategies in head and neck cancer.
    Gjini M; Ahmed S; Kalnicki S; Tomé WA; Garg MK; Kabarriti R; Brodin NP
    Acta Oncol; 2022 Sep; 61(9):1069-1074. PubMed ID: 35978529
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Can dose reduction to one parotid gland prevent xerostomia?--A feasibility study for locally advanced head and neck cancer patients treated with intensity-modulated radiotherapy.
    Anand AK; Jain J; Negi PS; Chaudhoory AR; Sinha SN; Choudhury PS; Kumar R; Munjal RK
    Clin Oncol (R Coll Radiol); 2006 Aug; 18(6):497-504. PubMed ID: 16909975
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recovery of Salivary Function: Contralateral Parotid-sparing Intensity-modulated Radiotherapy versus Bilateral Superficial Lobe Parotid-sparing Intensity-modulated Radiotherapy.
    Miah AB; Gulliford SL; Morden J; Newbold KL; Bhide SA; Zaidi SH; Hall E; Harrington KJ; Nutting CM
    Clin Oncol (R Coll Radiol); 2016 Sep; 28(9):e69-e76. PubMed ID: 26994893
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of parotid gland irradiation in the development of severe hyposalivation (xerostomia) after intensity-modulated radiation therapy for head and neck cancer: Temporal patterns, risk factors, and testing the QUANTEC guidelines.
    Owosho AA; Thor M; Oh JH; Riaz N; Tsai CJ; Rosenberg H; Varthis S; Yom SH; Huryn JM; Lee NY; Deasy JO; Estilo CL
    J Craniomaxillofac Surg; 2017 Apr; 45(4):595-600. PubMed ID: 28256385
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early Changes in Serial CBCT-Measured Parotid Gland Biomarkers Predict Chronic Xerostomia After Head and Neck Radiation Therapy.
    Rosen BS; Hawkins PG; Polan DF; Balter JM; Brock KK; Kamp JD; Lockhart CM; Eisbruch A; Mierzwa ML; Ten Haken RK; El Naqa I
    Int J Radiat Oncol Biol Phys; 2018 Nov; 102(4):1319-1329. PubMed ID: 30003997
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Parotid gland mean dose as a xerostomia predictor in low-dose domains.
    Gabryś HS; Buettner F; Sterzing F; Hauswald H; Bangert M
    Acta Oncol; 2017 Sep; 56(9):1197-1203. PubMed ID: 28502238
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predicting acute radiation induced xerostomia in head and neck Cancer using MR and CT Radiomics of parotid and submandibular glands.
    Sheikh K; Lee SH; Cheng Z; Lakshminarayanan P; Peng L; Han P; McNutt TR; Quon H; Lee J
    Radiat Oncol; 2019 Jul; 14(1):131. PubMed ID: 31358029
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of salivary gland function after treatment of head-and-neck tumors with intensity-modulated radiotherapy by quantitative pertechnetate scintigraphy.
    Münter MW; Karger CP; Hoffner SG; Hof H; Thilmann C; Rudat V; Nill S; Wannenmacher M; Debus J
    Int J Radiat Oncol Biol Phys; 2004 Jan; 58(1):175-84. PubMed ID: 14697436
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of head and neck cancer adaptive radiotherapy to spare the parotid glands and decrease the risk of xerostomia.
    Castelli J; Simon A; Louvel G; Henry O; Chajon E; Nassef M; Haigron P; Cazoulat G; Ospina JD; Jegoux F; Benezery K; de Crevoisier R
    Radiat Oncol; 2015 Jan; 10():6. PubMed ID: 25573091
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reducing xerostomia after chemo-IMRT for head-and-neck cancer: beyond sparing the parotid glands.
    Little M; Schipper M; Feng FY; Vineberg K; Cornwall C; Murdoch-Kinch CA; Eisbruch A
    Int J Radiat Oncol Biol Phys; 2012 Jul; 83(3):1007-14. PubMed ID: 22056067
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mid-treatment 18F-FDG PET imaging changes in parotid gland correlates to radiation-induced xerostomia.
    Trada Y; Lee MT; Jameson MG; Chlap P; Keall P; Moses D; Lin P; Fowler A
    Radiother Oncol; 2023 Sep; 186():109745. PubMed ID: 37330056
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Importance of the initial volume of parotid glands in xerostomia for patients with head and neck cancers treated with IMRT.
    Nishimura Y; Nakamatsu K; Shibata T; Kanamori S; Koike R; Okumura M; Suzuki M
    Jpn J Clin Oncol; 2005 Jul; 35(7):375-9. PubMed ID: 15976068
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase II study to assess the efficacy of amifostine for submandibular/sublingual salivary sparing during the treatment of head and neck cancer with intensity modulated radiation therapy for parotid salivary sparing.
    Rosenthal DI; Chambers MS; Weber RS; Eisbruch A
    Semin Oncol; 2004 Dec; 31(6 Suppl 18):25-8. PubMed ID: 15726519
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of salivary gland dosimetry on post-IMRT recovery of saliva output and xerostomia grade for head-and-neck cancer patients treated with or without contralateral submandibular gland sparing: a longitudinal study.
    Wang ZH; Yan C; Zhang ZY; Zhang CP; Hu HS; Tu WY; Kirwan J; Mendenhall WM
    Int J Radiat Oncol Biol Phys; 2011 Dec; 81(5):1479-87. PubMed ID: 20934262
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Parotid Gland Stem Cell Sparing Radiation Therapy for Patients With Head and Neck Cancer: A Double-Blind Randomized Controlled Trial.
    Steenbakkers RJHM; van Rijn-Dekker MI; Stokman MA; Kierkels RGJ; van der Schaaf A; van den Hoek JGM; Bijl HP; Kramer MCA; Coppes RP; Langendijk JA; van Luijk P
    Int J Radiat Oncol Biol Phys; 2022 Feb; 112(2):306-316. PubMed ID: 34563635
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Salivary gland-sparing other than parotid-sparing in definitive head-and-neck intensity-modulated radiotherapy does not seem to jeopardize local control.
    Chajon E; Lafond C; Louvel G; Castelli J; Williaume D; Henry O; Jégoux F; Vauléon E; Manens JP; Le Prisé E; de Crevoisier R
    Radiat Oncol; 2013 May; 8():132. PubMed ID: 23721062
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A prospective study of salivary function sparing in patients with head-and-neck cancers receiving intensity-modulated or three-dimensional radiation therapy: initial results.
    Chao KS; Deasy JO; Markman J; Haynie J; Perez CA; Purdy JA; Low DA
    Int J Radiat Oncol Biol Phys; 2001 Mar; 49(4):907-16. PubMed ID: 11240231
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Parotid gland sparing IMRT for head and neck cancer improves xerostomia related quality of life.
    van Rij CM; Oughlane-Heemsbergen WD; Ackerstaff AH; Lamers EA; Balm AJ; Rasch CR
    Radiat Oncol; 2008 Dec; 3():41. PubMed ID: 19068126
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prediction of Radiation-Induced Parotid Gland-Related Xerostomia in Patients With Head and Neck Cancer: Regeneration-Weighted Dose.
    van Rijn-Dekker MI; van Luijk P; Schuit E; van der Schaaf A; Langendijk JA; Steenbakkers RJHM
    Int J Radiat Oncol Biol Phys; 2023 Nov; 117(3):750-762. PubMed ID: 37150262
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dosimetric predictors of xerostomia for head-and-neck cancer patients treated with the smart (simultaneous modulated accelerated radiation therapy) boost technique.
    Amosson CM; Teh BS; Van TJ; Uy N; Huang E; Mai WY; Frolov A; Woo SY; Chiu JK; Carpenter LS; Lu HH; Grant WH; Butler EB
    Int J Radiat Oncol Biol Phys; 2003 May; 56(1):136-44. PubMed ID: 12694832
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.